Kairos Pharma Ltd. (NYSE American: KAPA) reported positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) in men with metastatic castration-resistant prostate cancer. The clinical-stage biopharmaceutical company presented the findings at the European Society for Medical Oncology meeting in Berlin, revealing that 86% of patients treated with ENV-105 combined with apalutamide demonstrated clinical benefit.
The study results showed all responding patients remained progression-free for at least four months, with half of the patients maintaining progression-free status beyond one year. Among nine evaluable patients, seven experienced prostate-specific antigen (PSA) reductions, supporting the therapy's potential to restore hormone responsiveness in patients who have developed resistance to standard treatments. This finding is particularly significant given that castration-resistant prostate cancer represents an advanced stage of disease where treatment options become increasingly limited.
The randomized trial, led by Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy of the treatment combination. ENV-105 represents a novel approach to cancer treatment as an antibody that specifically targets CD105, a protein identified as a key driver of resistance to various cancer therapies. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy often results in resistance and disease relapse.
The interim results suggest ENV-105 may effectively reverse drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. Beyond the current Phase 2 trial for castrate-resistant prostate cancer, ENV-105 is also being evaluated in a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology. The therapy's mechanism of action focuses on overcoming both drug resistance and immune suppression in cancer, utilizing structural biology approaches to develop innovative cancer therapeutics.
For investors and stakeholders seeking additional information about Kairos Pharma, the company maintains updated news and developments at https://ibn.fm/KAPA. The positive interim data from the Phase 2 trial represents a meaningful step forward in addressing the challenge of treatment resistance in advanced prostate cancer, potentially offering new hope for patients who have exhausted standard therapeutic options. The continued enrollment in the trial will provide further insights into the long-term safety profile and sustained efficacy of this novel treatment approach.
